MedPath

Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility

Not Applicable
Completed
Conditions
Unexplained Infertility
Registration Number
NCT03461601
Lead Sponsor
Ahmed Walid Anwar Murad
Brief Summary

A prospective randomized study included 210 women with Unexplained infertility subjected to combined ovarian stimulation and Intrauterine insemination (IUI). Two equal groups. Study group, subjected to uterine flushing with Human chorionic gonadotropin (HCG) one day before IUI and control group subjected to IUI alone.

Detailed Description

A prospective randomized study included 210 patients with Unexplained infertility subjected to coupled ovarian stimulation and Intrauterine insemination (IUI). Two equal groups. Study group, subjected to uterine flushing with Human chorionic gonadotropin (HCG) one day before IUI and control group subjected to IUI alone.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
210
Inclusion Criteria
  • Unexplained infertility (UI)
Exclusion Criteria
  • body mass index (BMI) ≥35 kg/m2,
  • Follicle Stimulating Hormone >10 International Unit /Litter in early follicular phase,
  • diagnosed cause of infertility, menstrual cycle irregularity,
  • ovarian cysts,
  • sever cervical stenosis,
  • former IUI,
  • ongoing pregnancy and
  • renal or hepatic diseases were all the exclusion criteria.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Live birth10 months of randomization

Defined as pregnancies maintained beyond 20 weeks of gestation

Secondary Outcome Measures
NameTimeMethod
Chemical pregnancyOne month after randomization

Defined as positive serum pregnancy test

Clinical pregnancyTwo months after randomization

Defined by the presence of gestational sac with fetal heartbeats on ultrasound scan or histological identification of trophoblastic tissue.

Adverse effectsone hour of the procedure

Nausea, vomiting, and pain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.